[Clinical evaluation of eosinophil cationic protein in asthmatic children]

Area of Science:

• Allergy and Immunology
• Pediatric Pulmonology
• Biomarker Research

Background:

• Asthma is a chronic inflammatory airway disease.
• Eosinophil cationic protein (ECP) is a marker of eosinophilic inflammation.
• Understanding ECP's role in pediatric asthma is crucial for diagnosis and management.

Purpose of the Study:

• To evaluate the clinical significance of serum and sputum eosinophil cationic protein (ECP) levels in asthmatic children.
• To correlate ECP levels with asthma attacks and eosinophil counts.
• To determine if ECP can serve as a biomarker for airway inflammation in pediatric asthma.

Main Methods:

• Serum and sputum ECP levels were measured in 93 asthmatic children and 16 healthy children.
• ECP levels were compared between asthmatic and healthy children, and during asthma attacks versus remission.
• Correlations between ECP levels, eosinophil counts, and disease severity were analyzed.

Main Results:

• Asthmatic children showed significantly higher serum ECP levels than healthy controls.
• Serum ECP levels were elevated during asthma attacks and correlated positively with peripheral blood eosinophil counts.
• Sputum ECP levels were significantly higher within two days of asthma attack onset, decreasing thereafter, and suggested to reflect local airway inflammation.

Conclusions:

• Both serum and sputum ECP levels are elevated during pediatric asthma attacks.
• Sputum ECP levels are a sensitive indicator of early-stage airway inflammation in asthma.
• ECP, particularly in sputum, shows potential as a valuable biomarker for assessing asthma activity and inflammation in children.